JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice.

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 13.64

Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ (2007) 8.87

The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ (2008) 7.47

An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study. BMJ (2009) 5.45

Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart (2006) 4.94

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet (2010) 4.23

Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study. BMJ (2011) 3.86

Evaluation of the Counterweight Programme for obesity management in primary care: a starting point for continuous improvement. Br J Gen Pract (2008) 3.16

Beyond odds ratios--communicating disease risk based on genetic profiles. Nat Rev Genet (2009) 3.01

Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. BMJ (2006) 2.67

The difference in blood pressure readings between arms and survival: primary care cohort study. BMJ (2012) 2.56

Automated electronic reminders to facilitate primary cardiovascular disease prevention: randomised controlled trial. Br J Gen Pract (2010) 2.32

Variability of office, 24-hour ambulatory, and self-monitored blood pressure measurements. Br J Gen Pract (2010) 2.16

Interpretive medicine: Supporting generalism in a changing primary care world. Occas Pap R Coll Gen Pract (2010) 2.00

Do known risk factors explain the higher coronary heart disease mortality in South Asian compared with European men? Prospective follow-up of the Southall and Brent studies, UK. Diabetologia (2006) 1.90

Using benefit-based tailored treatment to improve the use of antihypertensive medications. Circulation (2013) 1.89

Antiplatelet effects of dietary nitrate in healthy volunteers: involvement of cGMP and influence of sex. Free Radic Biol Med (2013) 1.78

The efficiency of cardiovascular risk assessment: do the right patients get statin treatment? Heart (2013) 1.73

Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study. Int J Clin Pract (2010) 1.68

Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol (2009) 1.68

Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther (2011) 1.68

Consensus statement on management of dyslipidemia in Indian subjects. Indian Heart J (2014) 1.57

Screening for future cardiovascular disease using age alone compared with multiple risk factors and age. PLoS One (2011) 1.56

The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. Eur Heart J (2009) 1.52

Clinical Utility of a Coronary Heart Disease Risk Prediction Gene Score in UK Healthy Middle Aged Men and in the Pakistani Population. PLoS One (2015) 1.51

Practitioner review: A critical perspective on gene-environment interaction models--what impact should they have on clinical perceptions and practice? J Child Psychol Psychiatry (2014) 1.51

Identifying undiagnosed diabetes: cross-sectional survey of 3.6 million patients' electronic records. Br J Gen Pract (2008) 1.50

Supporting self-care in general practice. Br J Gen Pract (2007) 1.50

Factors associated with statin treatment for the primary prevention of cardiovascular disease in people within 2 years following diagnosis of diabetes in Scotland, 2006-2008. Diabet Med (2014) 1.49

Identifying individuals for primary cardiovascular disease prevention in UK general practice: priorities and resource implications. Br J Gen Pract (2008) 1.49

Non-diabetic hyperglycaemia and cardiovascular risk: moving beyond categorisation to individual interpretation of absolute risk. Diabetologia (2010) 1.49

Patient factors influencing the prescribing of lipid lowering drugs for primary prevention of cardiovascular disease in UK general practice: a national retrospective cohort study. PLoS One (2013) 1.47

Ezetimibe-Statin Combination Therapy. Dtsch Arztebl Int (2016) 1.46

Impact of lipid-lowering therapy on the prevalence of dyslipidaemia in patients at high-risk of cardiovascular events in UK primary care - a retrospective database study. Int J Clin Pract (2013) 1.41

Uptake of the NHS Health Check programme in an urban setting. Fam Pract (2013) 1.39

Are older patients' cardiac rehabilitation needs being met? J Clin Nurs (2009) 1.39

Reducing blood pressure in people of different ages. BMJ (2008) 1.39

Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer (2009) 1.38

NHS health checks through general practice: randomised trial of population cardiovascular risk reduction. BMC Public Health (2012) 1.37

An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk. PLoS One (2011) 1.34

The rise of cholesterol testing: how much is unnecessary. Br J Gen Pract (2011) 1.27

Cardiovascular risk scores do not account for the effect of treatment: a review. Heart (2011) 1.19

Cross-sectional review of the response and treatment uptake from the NHS Health Checks programme in Stoke on Trent. J Public Health (Oxf) (2012) 1.19

Change in cardiovascular risk factors following early diagnosis of type 2 diabetes: a cohort analysis of a cluster-randomised trial. Br J Gen Pract (2014) 1.17

The Rise and Fall of Hypertension: Lessons Learned from Eastern Europe. Curr Cardiovasc Risk Rep (2011) 1.17

Patient and general practitioner attitudes to taking medication to prevent cardiovascular disease after receiving detailed information on risks and benefits of treatment: a qualitative study. BMC Fam Pract (2011) 1.16

Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization. Vasc Health Risk Manag (2010) 1.16

Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. Vasc Health Risk Manag (2007) 1.15

Are people with chronic diseases interested in using telehealth? A cross-sectional postal survey. J Med Internet Res (2014) 1.14

Neurocognitive function in HIV infected patients on antiretroviral therapy. PLoS One (2013) 1.11

Protocol for the 'e-Nudge trial': a randomised controlled trial of electronic feedback to reduce the cardiovascular risk of individuals in general practice [ISRCTN64828380]. Trials (2006) 1.09

Can admission and fasting glucose reliably identify undiagnosed diabetes in patients with acute coronary syndrome? Diabetes Care (2008) 1.09

Cardiovascular screening in rheumatoid arthritis: a cross-sectional primary care database study. BMC Fam Pract (2013) 1.08

Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study. BMJ (2012) 1.08

Road traffic accidents in Libya: An undeclared War. Libyan J Med (2008) 1.08

Adolescent type 1 Diabetes Cardio-renal Intervention Trial (AdDIT). BMC Pediatr (2009) 1.08

A framework for quantifying net benefits of alternative prognostic models. Stat Med (2011) 1.08

Prevalence, risk factors and associations of primary Raynaud's phenomenon: systematic review and meta-analysis of observational studies. BMJ Open (2015) 1.07

Distribution of 10-year and lifetime predicted risk for cardiovascular disease in the Indian Sentinel Surveillance Study population (cross-sectional survey results). BMJ Open (2011) 1.07

Cost of illness for chronic stable angina patients enrolled in a self-management education trial. Can J Cardiol (2008) 1.07

Obesity and the overworked GP. Br J Gen Pract (2006) 1.06

Design and rationale of the MR-INFORM study: stress perfusion cardiovascular magnetic resonance imaging to guide the management of patients with stable coronary artery disease. J Cardiovasc Magn Reson (2012) 1.05

Orange juice-derived flavanone and phenolic metabolites do not acutely affect cardiovascular risk biomarkers: a randomized, placebo-controlled, crossover trial in men at moderate risk of cardiovascular disease. Am J Clin Nutr (2015) 1.05

Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trials. PLoS One (2013) 1.03

Inclusion of stroke as an outcome and risk equivalent in risk scores for primary and secondary prevention of vascular disease. Circulation (2010) 1.01

Within-subject blood pressure level--not variability--predicts fatal and nonfatal outcomes in a general population. Hypertension (2012) 1.00

The cardiovascular response to arousal from sleep decreases with age in healthy adults. Sleep (2008) 0.99

Cardiovascular risk. Br J Clin Pharmacol (2012) 0.97

Mixed methods evaluation of targeted case finding for cardiovascular disease prevention using a stepped wedged cluster RCT. BMC Public Health (2012) 0.96

Impact of time since last caloric intake on blood glucose levels. Eur J Epidemiol (2011) 0.96

Increasing socioeconomic inequalities in first acute myocardial infarction in Scotland, 1990-92 and 2000-02. BMC Public Health (2009) 0.95

The impact of individualised cardiovascular disease (CVD) risk estimates and lifestyle advice on physical activity in individuals at high risk of CVD: a pilot 2 x 2 factorial understanding risk trial. Cardiovasc Diabetol (2008) 0.95

Physician and patient management of type 2 diabetes and factors related to glycemic control in Spain. Patient Prefer Adherence (2008) 0.95

The independent relationship between triglycerides and coronary heart disease. Vasc Health Risk Manag (2009) 0.95

Clinical prediction rules in practice: review of clinical guidelines and survey of GPs. Br J Gen Pract (2014) 0.94

Zero end-digit preference in recorded blood pressure and its impact on classification of patients for pharmacologic management in primary care - PREDICT-CVD-6. Br J Gen Pract (2007) 0.94

A cluster randomised controlled trial of a pharmacist-led collaborative intervention to improve statin prescribing and attainment of cholesterol targets in primary care. PLoS One (2014) 0.93

Plant science and human nutrition: challenges in assessing health-promoting properties of phytochemicals. Plant Cell (2011) 0.93

Concomitant reduction of low-density lipoprotein-cholesterol and biomarkers of inflammation with low-dose simvastatin therapy in patients with type 1 diabetes. J Clin Endocrinol Metab (2007) 0.93

Framingham risk prediction equations for incidence of cardiovascular disease using detailed measures for smoking. Heart Int (2010) 0.93

Prediction of cardiovascular risk using Framingham, ASSIGN and QRISK2: how well do they predict individual rather than population risk? PLoS One (2014) 0.92

Coronary heart disease in Indian Asians. Glob Cardiol Sci Pract (2014) 0.91

Common carotid intima-media thickness does not add to Framingham risk score in individuals with diabetes mellitus: the USE-IMT initiative. Diabetologia (2013) 0.91

The effectiveness of German disease management programs (DMPs) in patients with type 2 diabetes mellitus and coronary heart disease: results from an observational longitudinal study. Diabetol Metab Syndr (2015) 0.91

Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). Cardiovasc Diabetol (2010) 0.90

The Sandwell Project: a controlled evaluation of a programme of targeted screening for prevention of cardiovascular disease in primary care. BMC Public Health (2008) 0.89

An evaluation of Birmingham Own Health telephone care management service among patients with poorly controlled diabetes. A retrospective comparison with the General Practice Research Database. BMC Public Health (2011) 0.89

Association of a sequence variant in DAB2IP with coronary heart disease. Eur Heart J (2011) 0.89

Diagnostic triage and the role of natriuretic peptide testing and echocardiography for suspected heart failure: an appropriateness ratings evaluation by UK GPs. Br J Gen Pract (2011) 0.88

Validation of the Framingham general cardiovascular risk score in a multiethnic Asian population: a retrospective cohort study. BMJ Open (2015) 0.88

Therapeutics of diabetes mellitus: focus on insulin analogues and insulin pumps. Exp Diabetes Res (2010) 0.87

Guidance in Subclinical Hyperthyroidism and Subclinical Hypothyroidism: Are We Making Progress? Eur Thyroid J (2015) 0.87

A diet rich in high-glucoraphanin broccoli interacts with genotype to reduce discordance in plasma metabolite profiles by modulating mitochondrial function. Am J Clin Nutr (2013) 0.87

Long term health consequences of polycystic ovarian syndrome: a review analysis. Hippokratia (2009) 0.87

Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom. Br J Clin Pharmacol (2008) 0.86

Impact of an informed choice invitation on uptake of screening for diabetes in primary care (DICISION): trial protocol. BMC Public Health (2009) 0.86

Does pulmonary rehabilitation address cardiovascular risk factors in patients with COPD? BMC Pulm Med (2011) 0.86

Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD. Kidney Int Suppl (2011) (2013) 0.86

Comprehensive cardiovascular risk management--what does it mean in practice? Vasc Health Risk Manag (2007) 0.86

Non-steroidal anti-inflammatory drugs for the treatment of pain and immobility-associated osteoarthritis: consensus guidance for primary care. BMC Fam Pract (2012) 0.85

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med (2002) 101.79

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med (2001) 56.11

Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA (1995) 38.40

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (2000) 35.06

Banting lecture 1988. Role of insulin resistance in human disease. Diabetes (1988) 33.22

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 29.25

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med (1995) 28.35

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet (1998) 26.64

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med (1998) 25.66

Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet (1990) 25.12

Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ (2004) 24.88

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care (1997) 23.95

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 23.07

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med (2001) 22.32

A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. JAMA (1992) 22.27

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet (2005) 21.91

Cardiovascular disease risk profiles. Am Heart J (1991) 21.65

Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med (2001) 20.18

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med (2003) 20.06

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA (1998) 19.64

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med (1992) 18.74

Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J (2003) 17.80

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet (2003) 17.34

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med (2001) 17.24

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 17.19

Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med (1999) 16.57

Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet (2003) 16.51

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet (2004) 16.23

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med (1987) 13.50

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet (2005) 12.92

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med (2005) 12.72

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract (1995) 12.51

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA (2002) 12.29

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA (2005) 12.00

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ (1994) 11.85

An updated coronary risk profile. A statement for health professionals. Circulation (1991) 11.71

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ (2003) 11.21

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (2004) 11.13

Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med (2001) 10.54

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA (1999) 10.52

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med (2001) 10.36

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA (2004) 9.91

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med (1999) 9.83

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet (2002) 9.48

Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet (1989) 9.27

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet (1997) 9.18

Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA (1999) 9.18

The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care (1999) 9.16

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA (2001) 9.16

Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet (1994) 9.13

The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) (2001) 8.45

Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med (1997) 8.43

Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens (2004) 8.32

Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med (2004) 8.07

British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ (2004) 7.92

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care (1997) 7.85

A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med (2003) 7.74

Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA (1998) 7.67

Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet (1999) 7.65

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet (1999) 7.56

Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA (2003) 7.42

Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence. BMJ (1997) 7.37

Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med (2002) 7.32

A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol (1990) 7.24

Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation (2003) 7.22

Chronic infections and coronary heart disease: is there a link? Lancet (1997) 7.18

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 6.87

Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ (1990) 6.70

15-year longitudinal study of blood pressure and dementia. Lancet (1996) 6.44

Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: cross sectional study. BMJ (1999) 6.40

Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA (2004) 6.28

Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ (1993) 6.23

Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet (1998) 6.20

European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens (2003) 5.94

Cigarette smoking and progression of atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. JAMA (1998) 5.80

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA (1995) 5.80

Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet (2002) 5.77

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA (2003) 5.67

beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ (1999) 5.66

Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA (1996) 5.63

Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ (2001) 5.55

Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J (2005) 5.40

Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med (1984) 5.35

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care (2004) 5.34

MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA (2002) 5.29

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med (1995) 5.22

Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet (2000) 4.93

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens (2003) 4.91

Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation (1997) 4.81

Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ (2003) 4.74

Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension (2003) 4.71

The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke (2003) 4.63

Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation (2002) 4.56

Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA (1996) 4.54

Coronary heart disease in south Asians overseas: a review. J Clin Epidemiol (1989) 4.53

Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care (2003) 4.50

Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA (1997) 4.37

Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens (2004) 8.32

Myocardial perfusion scintigraphy: the evidence. Eur J Nucl Med Mol Imaging (2004) 2.41

Validation of the Microlife BP 3BTO-A oscillometric blood pressure monitoring device according to a modified British Hypertension Society protocol. Blood Press Monit (2002) 1.03

Guidelines from the British Hypertension Society: is hypertension really a disease? BMJ (2004) 0.90

Joint UK societies' 2014 consensus statement on renal denervation for resistant hypertension. Heart (2014) 0.85

Which antibiotic prophylaxis guidelines for infective endocarditis should Canadian dentists follow? J Can Dent Assoc (2007) 0.81

Guidelines from the British Hypertension Society: BHS is set to bankrupt NHS. BMJ (2004) 0.77

Guidelines from the British Hypertension Society: cholesterol values seem to diverge. BMJ (2004) 0.75

Guidelines from the British Hypertension Society: life in the real world may not allow recommendations to be implemented. BMJ (2004) 0.75

Setting up a myocardial perfusion scintigraphy service: clinical and business aspects. Heart (2005) 0.75

Guidelines from the British Hypertension Society: numbers are missing. BMJ (2004) 0.75

Diabetes UK Position Statement. Competency frameworks in diabetes. Diabet Med (2015) 0.75

Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. A mini-symposium held at the British Hypertension Society Meeting, September 2005. J Renin Angiotensin Aldosterone Syst (2006) 0.75